News Release 

Filled buprenorphine prescriptions for opioid use disorder during COVID-19 pandemic

JAMA Internal Medicine

Research News

What The Study Did: The COVID-19 pandemic has disrupted health care delivery in the United State, and researchers in this study examined changes in total U.S. retail pharmacy sales and sales of buprenorphine products with a U.S. Food and Drug Administration-approved indication for treatment of opioid use disorder.

Authors: Thuy D. Nguyen, Ph.D., of the University of Michigan in Ann Arbor, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link


Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.


Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.